Losing weight has become a difficult endeavour for Charlotte, North Carolina kindergarten teacher Grey Beard. She had never seen long-lasting effects from any of the five programmes she had attempted in her life.

Her fortune began to turn around the previous year when she noticed an Instagram advertisement for the Ro Body Programme, a brand-new product from online health business Ro. Advertisement: Qualifying patients might be administered GLP-1s, the highly talked-about class of obesity medications that have become a lucrative industry in recent years.

Beard, 47, claimed that when she had previously asked for a GLP-1 prescription, her doctor “wouldn’t even try” to have it authorised because she assumed her insurance company wouldn’t pay for the pricey drug. The monthly cost of GLP-1s, before insurance and other rebates, is around $1,000.

Patients enrolled in Ro’s Body Programme may be administered a GLP-1, such as the diabetic medication Ozempic or the weight-loss medication Wegovy from Novo Nordisk, and scheduled monthly checkups with a physician. In addition, they receive a curriculum for instruction, round-the-clock messaging, one-on-one coaching with nurses, and help with the intricacies of insurance.

When Beard joined the programme in early January of last year, her weight was 210 pounds. Since then, she has shed forty pounds and acts as Ro’s spokesperson. After insurance coverage, she pays $30 a month for the GLP-1 therapy plus a $145 monthly programme cost. She also doesn’t intend to depart.

Beard remarked, “Even if I have to stay on it forever, I’m fine.”

Founded as Roman in 2017, Ro is among an increasing number of digital health startups hoping to leverage the skyrocketing demand for GLP-1s by providing customers with additional services and programmes beyond the prescription drugs. There may be a huge opportunity. By 2030, 15 million individuals in the United States are expected to be using anti-obesity medications, and Goldman Sachs analysts project that the sector may generate $100 billion in sales annually by then.

The GLP-1 family also contains the diabetic medication Mounjaro and the very well-liked weight-loss medication Zepbound from Eli Lilly, in addition to Wegovy and Ozempic. GLP-1s are similar to a hormone that the stomach produces to control blood sugar levels and reduce hunger.

Like Ro, a number of non-pharmaceutical companies have launched products targeted at GLP-1 patients or expanded their services to cover the well-known drugs. These companies include Calibrate, Sesame, Omada Health, Noom, Hims & Hers, and even telehealth industry veterans Teladoc Health and WeightWatchers.

Investors are supporting them in the interim.

On May 20, shares of Ro’s rival Hims & Hers surged by 28% on the announcement that the firm is now providing compounded GLP-1 injections in addition to its oral pharmaceutical kits. The business is certain that consumers will have access to a steady supply of the injections, CEO Andrew Dudum told CNBC.

One of the biggest obstacles facing businesses in the industry is a paucity of supplies since rising demand has made it harder for many patients to get the treatments they need.

The World Health Organisation, which stated in January that the combination of shortages and the “increased circulation of falsified versions” is particularly problematic for patients with Type 2 diabetes who depend on the medication for disease management, also reports a rise in counterfeit products.

Zachariah Reitano, the creator of Ro, and other business leaders are not deterred by this.

Ro was not initially a firm that catered to dieters. Before expanding to include treatments for hair loss and other disorders, Reitano first started selling erectile dysfunction medicines online.

Following the FDA’s approval of Wegovy in 2020, Ro shifted his focus to managing obesity. According to Reitano, patient queries began to come in by the “tens of thousands” the following year.

Presently, Ro is pouring a lot of money into its GLP-1 programme through influencer campaigns that highlight patients like Beard as well as digital advertisements, TV advertising, and posters that line tube stations.

GLP-1s are similar to a “jetpack for positive behaviour change,” according to Reitano. According to him, patients often notice a 30% decrease in caloric consumption, increase their activity, and eat better.

“There’s a positive flywheel once you get a little momentum and lose a little weight because you’re sleeping better, have more energy, can work out, and can eat better,” Reitano explained.

According to PitchBook, Ro has garnered almost $1 billion in investment thus far. Prior to a sharp decline in tech stocks and the collapse of the initial public offering market, which led many firms to drastically reduce their values, the company was valued at over $7 billion in early 2022.

With more than 60 years of experience, WeightWatchers is the name most likely most associated with weight loss programmes in the United States.

With a behavioral-support programme that is accessible through its general membership subscription, which starts at $23 per month, the business entered the GLP-1 market in December. Whether a member obtains a GLP-1 prescription from their primary care physician or through the newly launched WeightWatchers Clinic in conjunction with the behavioural programme, they are eligible to participate.

WeightWatchers immediately discovered that, due to GLP-1s’ ability to reduce appetite, patients on the medication need a whole new programme, according to chief scientific officer Gary Foster.

In an interview, Foster stated, “They don’t need help with what to do for dessert or how to deal with the bread on the table at a restaurant.” “That’s about 50–60% of what we would do for individuals who don’t take medication.”

Clinic members who take part in the GLP-1 programme must pay an extra cost, which starts at $99 per month, in order to have exclusive access to care team coordinators, licenced dieticians, and fitness specialists.

Earlier this month, WeightWatchers said in its first-quarter statistics that 87,000 people had signed up for the clinic; however, not all of them are taking GLP-1s. According to the article, the business anticipates having 140,000–160,000 clinic members by the end of the year.

It hasn’t been sufficient to alter WeightWatchers’ course. Due to worries about the company’s debt burden, its primary weight loss business, and Oprah Winfrey’s announced exit from the board in February, the stock has fallen 83% so far this year.

“The landscape is quite exciting” in regards to GLP-1s and their effect on weight reduction, according to Foster. “I think the fact that there are more tools in the toolbox to help people trying to manage their weight is something we should all really be delighted about and celebrate.”

Jennifer VanGilder, a 51-year-old professor of economics at Collegeville, Pennsylvania’s Ursinus College, claimed to have attempted a wide range of weight-loss strategies, including rigid diets and programmes like the now-defunct Jenny Craig. She had been thinking about having bariatric surgery until she learned about a programme offered by the digital health business Calibrate.  

One of the first businesses to treat obesity using a combination of GLP-1s and one-on-one coaching was Calibrate, which was formed in 2019. The programme demands an initial three-month commitment and costs $199 each month, not including the prescription.

VanGilder began receiving the weekly Ozempic diabetic injection with the intention of losing weight when he enrolled about four years ago. Later on, she moved to Wegovy.

Although GLP-1s aren’t a magic medication, VanGilder said that she shed about 100 pounds of her 242 pounds by taking them and working hard. VanGilder claimed that the main distinction between Calibrate and earlier weight loss attempts is that the former doesn’t feel like a diet.

VanGilder stated, “That’s why I’ve been able to stay on it for as long as I have.”

Among the few businesses that consistently publishes reports describing the outcomes of its weight reduction programme is Calibrate. The data from about 16,000 members who had finished the programme for at least a year as of October, as well as a smaller sample of patients who persisted for a longer period of time, were analysed by the corporation in its 2024 report.

According to the findings, patients lost an average of 16.2% of their body weight at 12 months into the programme, 17.3% at 18 months, and 17.9% at 24 months.

“We can deliver faster, better results than some of the leading GLP-1 clinical trials,” vice president of clinical development at Calibrate, Dr. Kristin Baier, stated in an interview.

But over the last few years, Calibrate has encountered some significant roadblocks.

The firm had to fire hundreds of workers between 2022 and 2023 due to a mix of supply constraints, insurance issues, and the general market downturn, following its $100 million venture financing round at the tech sector’s zenith in 2021.

The business was purchased by Madryn Asset Management, a private equity firm, in October at a discount.

The industry was deemed “ill equipped” by Calibrate CEO Rob MacNaughton to handle the “dramatic demand that led to, at some point, severely, severely constrained supply” of GLP-1s in the previous year.

The business is still pushing its GLP-1 service under the new management, claiming that it is crucial since the medications alone are insufficient.

Baier stated, “GLP-1 medications are a tool, even though they are safe and effective.” “The treatment is not limited to them.”

Ro’s Reitano stated that his business had to briefly halt advertising last year due to a lack of Wegovy and other GLP-1s. According to Ro, patients in its programme who were unable to pick up their medication within 30 days of getting a prescription also received credits and reimbursements.

Reitano noted that in order to assist patients in navigating supply challenges, Ro has established “both technical tools and operations.” This involves moving prescriptions to other pharmacies in accordance with their GLP-1 supply and patient’s location. In order to arrange such transfers, the business called 50,000 pharmacies nationwide in July and August, according to Reitano.

Zepbound was added to Ro’s drug portfolio once it was approved in the United States in November.

“We added that to our formulary, and that’s really when we started advertising again because we had confidence that we’d be able to get patients an option,” Reitano said.

Ro CEO on the effects of weight reduction medications and telemedicine However, issues with insurance still exist.

The expense of paying for thousands of patients’ treatments has led to several companies removing weight reduction medications from their policies. By law, weight reduction medications cannot be covered by the federal Medicare programme unless a prescription is written for another recognised health benefit, such diabetes or cardiovascular disease.

Commercial savings card programmes are offered by Eli Lilly and Novo Nordisk with the goal of increasing access to their GLP-1s. Eli Lilly offers Zepbound prescriptions at a discounted price of $25 per month for those with insurance. Additionally, patients without insurance may be able to obtain the medication for as little as $550 a month.

Even after introducing its new weight loss programme in December, Hims & Hers chose not to enter the GLP-1 market at first due to the high costs and challenging access. Dr. Craig Primack, senior vice president of weight management at Hims, said the company chose to provide treatment plans based on medications that had been researched and prescribed for decades. 

In an interview with CNBC in March, Primack stated, “We’re going to have people, for one reason or another, who either don’t want an injection at this point or are just looking for a different alternative.” “We have been using these tools in our field for a very long time.”

Hims announced this week that users of the site can now obtain compounded GLP-1 drugs with a prescription from a certified healthcare professional. Hims stated that when supplies are reliably accessible, it intends to provide its clients access to branded GLP-1 drugs. The monthly cost of the company’s oral pharmaceutical kits is $79, while the monthly cost of its compounded GLP-1 injections is $199.

According to Dudum, the business has some exclusivity with the facility and has worked with one of the biggest generic producers in the United States. He added the FDA has authority over the manufacturer.

Prior to adding compounded GLP-1 injections to its weight reduction menu, Hims stated that it anticipated the programme will bring in more than $100 million by the end of 2025.

Since beginning the Body Programme, Beard, the Ro client, has had to make some adjustments. She was able to take Wegovy at first without having to pay for medication out of pocket because of her insurance and a Novo Nordisk savings card programme. However, the medicine didn’t work for her, so she moved to Zepbound.

Beard claims that, despite a few bumps along the road, the programme has mostly been a “seamless” addition to her daily life and that she no longer obsesses about food. She even succeeded in enrolling a relative.

“Why stop taking it when there aren’t any negative side effects?” she said, adding that it had assisted them in reaching their desired weight.

(Adapted from CNBC.com)

Categories: Economy & Finance, Entrepreneurship, Regulations & Legal, Strategy, Sustainability